INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
MWN-AI** Summary
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company focused on inflammation and immunology, will have its CEO, David Moss, participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22-23, 2025, in New York City. The panel discussion, moderated by biotechnology research expert Jason McCarthy, Ph.D., will highlight INmune Bio’s innovative platform, CORDStrom™, aimed at treating Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe pediatric condition that affects multiple organs.
CORDStrom™ represents INmune Bio's commitment to addressing ultra-rare diseases through its advanced, proprietary technology involving human umbilical cord-derived mesenchymal Stromal/Stem cells (hucMSCs). The platform has just completed a randomized trial for RDEB, underscoring the company's dedication to finding effective treatments for patients suffering from conditions with significant unmet medical needs.
In addition to CORDStrom™, INmune Bio develops therapies targeting innate immune responses through three main platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform aims to neutralize soluble TNF, which is implicated in various diseases. Another initiative, INKmune®, focuses on harnessing a patient's natural killer cells to combat minimal residual disease in cancer patients, with ongoing trials in metastatic castration-resistant prostate cancer.
David Moss will also be available for one-on-one meetings during the summit, providing investors and interested parties a chance to learn more about INmune Bio’s future prospects. As the company continues its clinical trials and innovation in drug development, its participation in such panels is vital for visibility and engagement within the biotech sector. For registration details and additional information, visit the Maxim Group’s official site.
MWN-AI** Analysis
As INmune Bio, Inc. (NASDAQ: INMB) prepares for its participation in the Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22-23, 2025, investors should closely monitor the developments surrounding its innovative therapies targeted at rare diseases. The focus on CORDStrom™, INmune Bio's proprietary platform for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB), positions the company at the forefront of addressing critical unmet medical needs. RDEB is an ultra-rare condition affecting numerous organ systems, deserving heightened attention within the biotech landscape.
Investors should note the significance of Mr. David Moss’s discussion on CORDStrom™, especially as the company has recently completed a blinded randomized trial. Positive outcomes from clinical trials can potentially catalyze stock price appreciation, making this announcement impactful for market sentiment. With the inherent risks associated with clinical-stage biotech firms, it is essential to weigh these opportunities against potential hurdles, including FDA approval timelines and funding considerations.
Participation in high-visibility events like the Maxim Growth Summit can enhance investor confidence and attract institutional interest. Analysts should also consider the company's broader pipeline, which includes the DN-TNF platform and INKmune®, as these programs might mitigate risks tied to CORDStrom™ while potentially diversifying revenue streams in the future.
Potential investors might want to adopt a cautious yet optimistic stance, recognizing both the high rewards and inherent risks in biotech investments. Keeping a pulse on investor relations activities and market responses during and after the Summit could provide critical insights into INmune Bio's trajectory. It may also be prudent to remain vigilant regarding broader market trends impacting biotechnology, particularly concerning regulatory approvals and funding environments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025 at the Hard Rock Hotel in New York City.
The panel will be moderated by Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research. Mr. Moss will discuss Inmune Bio’s CORDStrom™, the company’s advanced cell platform for the systematic treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), an ultra-rare pediatric disease affecting nearly every organ in the body except the brain.
Date: October 22, 2025
Time: 8:30am ET
Register: https://www.meetmax.com/sched/event_124447/conference_register.html
Mr. Moss will be available for one-on-one meetings throughout the conference.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. The second program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. The third program, INKmune®, is designed to prime a patient’s natural killer cells to eliminate minimal residual disease in patients with cancer and is currently in a trial in metastatic castration-resistance prostate cancer. To learn more, please visit www.inmunebio.com .
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The independent and employee-owned firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA, SIPC, and NASDAQ. To learn more about Maxim Group LLC, visit maximgrp.com.
For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of diseases, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™, pegipanermin ), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contacts:
David Moss
Chief Executive Officer
(858) 964-3720
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ**
How could participation in the Dermatologic Rare Disease Panel at the Maxim Growth Summit impact INmune Bio Inc. (NASDAQ: INMB) in terms of investor interest and market perception?
What potential challenges might INmune Bio Inc. (NASDAQ: INMB) face in the commercialization of CORDStrom™ following its recent clinical trials, and how are they preparing to address these?
Considering the risks mentioned in the press release, what strategies does INmune Bio Inc. (NASDAQ: INMB) have in place to secure additional funding for ongoing clinical trials and development efforts?
How does INmune Bio Inc. (NASDAQ: INMB) plan to leverage the advancements of its DN-TNF and INKmune® product platforms in future clinical trials and presentations at investor summits?
**MWN-AI FAQ is based on asking OpenAI questions about INmune Bio Inc. (NASDAQ: INMB).
NASDAQ: INMB
INMB Trading
-4.53% G/L:
$1.58 Last:
313,312 Volume:
$1.66 Open:
